Loading data for SPRY — first visit, this takes a few seconds.
ARS Pharmaceuticals, Inc. (SPRY)
NasdaqGM: SPRY
· 实时价格 · USD
4.76
-0.30 (-5.93%)
收盘价： Sep 11, 2026, 3:59 PM
4.82
+1.26%
盘后: 7:43 PM
股价、关键数字和最新消息，都在这一页。
ARS Pharmaceuticals, Inc.（SPRY）股价、分析与数据
-5.93% (1D)
| 买价 | 3.89 |
| 市值 | 473M |
| 营收（TTM） | 117M |
| 净利润（TTM） | -215M |
| 1.00 | |
| -2.18 | |
| n/a | |
| -5.31 | |
| 市净率（TTM） | 37.78 |
| 市销率（TTM） | 4.05 |
| 财报日期 | Nov 10, 2026 |
| 卖价 | 6.72 |
| 成交量 | 2,570,805 |
| 20日均量 | 1,998,462 |
| 开盘价 | 5.13 |
| 前收盘价 | 5.06 |
| 日内区间 | 4.73 - 5.18 |
| 52周区间 | 4.73 - 13.15 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 SPRY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California....
公司完整简介财报意外
ARS Pharmaceuticals 已于 Aug 13, 2026 发布季度财报：
- 营收为 $22.68M 低于预期 $0, ， 184.47% 同比增长.
- 每股收益为 -0.63 低于预期 -0.14, ， -36.96% 同比下滑.
第 1 页，共 2 页